Astex Pharmaceuticals, Inc.
GPTKB entity
Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired_by_Otsuka_Pharmaceutical
|
| gptkbp:advertising |
Targeted marketing for oncology drugs
|
| gptkbp:budget |
Available on the website
|
| gptkbp:businessModel |
Focus on partnerships and collaborations
|
| gptkbp:CEO |
gptkb:Dr._Harren_Jhoti
|
| gptkbp:clinicalTrials |
Targeted therapies
Collaboration with hospitals Published in medical journals Multiple ongoing trials Phase I, II, and III trials |
| gptkbp:collaborations |
Various pharmaceutical companies
With academic institutions Partnerships with research institutions |
| gptkbp:community_engagement |
Involvement in local health initiatives
|
| gptkbp:community_involvement |
Support for local charities
|
| gptkbp:culturalHeritage |
Commitment to workplace diversity
|
| gptkbp:drugInterdiction |
Fragment-based drug discovery
Diverse pipeline of drug candidates Innovative platforms for drug discovery |
| gptkbp:employeeCount |
Approximately 200
|
| gptkbp:feedback |
Focus on improving patient outcomes
|
| gptkbp:financialPerformance |
Consistent revenue growth
Tracked_on_NASDAQ |
| gptkbp:focus |
Drug discovery
|
| gptkbp:founded |
gptkb:Cambridge,_United_Kingdom
1990 |
| gptkbp:founder |
gptkb:Harold_P._Smith
|
| gptkbp:funding |
$100 million (2020)
$30 million (2020) |
| gptkbp:future_plans |
Expand into new therapeutic areas
Expand oncology portfolio |
| gptkbp:headquarters |
gptkb:Pleasanton,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astex Pharmaceuticals, Inc.
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:investmentFocus |
Venture capital funding
Various institutional investors Transparent communication with investors |
| gptkbp:keyPeople |
gptkb:Dr._James_S._McCafferty
|
| gptkbp:market |
$300 million (2020)
|
| gptkbp:notableFeature |
gptkb:Dacogen
Zydelig |
| gptkbp:partnerships |
gptkb:Otsuka_Pharmaceutical_Co.,_Ltd.
|
| gptkbp:patentCitation |
Numerous patents in drug development
|
| gptkbp:products |
Cancer therapies
|
| gptkbp:publications |
Numerous peer-reviewed articles
|
| gptkbp:reach |
International collaborations
|
| gptkbp:regulatoryCompliance |
FDA_approvals_for_several_drugs
|
| gptkbp:research |
gptkb:Dr._David_A._Smith
|
| gptkbp:research_areas |
Oncology
Hematology Solid tumors |
| gptkbp:researchAndDevelopment |
Significant investment in R&D
|
| gptkbp:revenue |
$50 million (2020)
$5 million (2020) |
| gptkbp:sells |
NASDAQ:_ASTX
|
| gptkbp:subsidiary |
gptkb:Astex_Pharmaceuticals_Ltd.
|
| gptkbp:sustainability_initiatives |
Commitment to environmental practices
|
| gptkbp:team |
Experienced management team
|
| gptkbp:training |
Focus on continuous education
|
| gptkbp:type |
Public company
|
| gptkbp:website |
www.astx.com
|